On the morning of August 10, a delegation led by Feng Fei, Secretary of the CPC Hainan Provincial Committee, visited Hainan Simcere Pharmaceutical to learn about its biopharmaceutical innovative development and investigate the workshop of XIANNUOXIN, China's first anti-COVID-19 innovative drug targeted 3CL protease. The visit was accompanied by Luo Zengbin, Standing Committee Member of the CPC Hainan Provincial Committee and Secretary of the CPC Haikou Municipal Committee, Xie Jing, Vice Governor of Hainan Province, Luo Qingming, Vice Chairman of the CPPCC Hainan Provincial Committee, as well as the persons in charge of local authorities such as Hainan Reform Deepening Office, Hainan Provincial Department of Industry and Information Technology, Hainan Medical Products Administration, and Haikou People's Government.
Dr. Tang Renhong, chairman of Simcere Zaiming, reported on the innovative drug R&D strategies and project progression of Hainan Simcere Pharmaceutical, highlighting the plans of Simcere Zaiming, real-study study progression of XIANNUOXIN, as well as two achievements in promoting coordinated development between Lecheng International Medical Pilot Zone and Haikou Hi-Tech Zone—the localizing progression of the innovative drug COSELA and the incoming production of daridorexant hydrochloride for treatment of insomnia in Lecheng.
The Scene Picture of the Visit of Feng Fei, Secretary of the CPC Hainan Provincial Committee, in Hainan Simcere Pharmaceutical
Ren Jinsheng, chairman of Simcere Pharmaceutical, expressed gratitude to the CPC Hainan Provincial Committee and the Provincial Government for their support all the time and emphasized that Simcere Pharmaceutical will continue to increase R&D investment in innovative drugs, expand international cooperation with Hainan Free Trade Port as the place of origin, and insist on the compliant operation and specialized marketing.
Feng Fei adequately recognized the innovative development results of Simcere Pharmaceutical in Hainan and strongly encouraged the exploration of translation mode of the innovation achievements based on real-world study in the Lecheng International Medical Pilot Zone. Feng Fei emphasized that the complete approval of XIANNUOXIN is of great significance in bringing innovation achievements to COVID-19 patients early. At the same time, Simcere Pharmaceutical is expected to stick with collaborative innovation and bring together more elements of innovation, injecting new impetus into the innovative development of the biopharmaceutical industry in Hainan.
Recently, Hainan Simcere Pharmaceutical has been localizing multiple innovative drugs. At the beginning of this year, the application to localize COSELA® (Trilaciclib Hydrochloride for Injection), the world’s first-in-class innovative drug for the protection of comprehensive marrows, was accepted. Upon approval, the production is expected to be put into production in the first quarter of next year. With the production cost drastically reduced, the accessibility of the drug is expected to be greatly improved. On July 20, daridorexant hydrochloride, a novel drug for the treatment of insomnia jointly developed by Simcere Pharmaceutical and Idorsia, obtained the approval for clinical trials from NMPA, with the clinical application to be localized and the read-world study to be launched in Lecheng.